Medical Doctor Program year 2023 Reported 2021–2023 Source: CMS Open Payments, 2026 publication

Suzy Nashed

Psychiatry Elkton, MD Medical Doctor

NPI 1629062492 CMS profile 255501

111 W High St, Suite 315, Elkton, MD 21921

Open in the dashboard

General payments

$1,035

41 records reported · program years 2021–2023

Research payments

$0

Paid to them · None reported · program years 2021–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Suzy Nashed of Elkton, MD is reported in the CMS Open Payments database as having received $1,035 across 41 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 71st percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $382 14
2022 General $403 19
2021 General $250 8

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Suzy Nashed
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Suzy Nashed were reported at $0. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Suzy Nashed Psychiatry median Middle half National median
2019 $0 $184 $59–$605 $163
2020 $0 $119 $36–$372 $114
2021 $250 $143 $43–$576 $132
2022 $403 $153 $50–$590 $149
2023 $382 $170 $56–$651 $160
2024 $0 $179 $57–$673 $164
2025 $0 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2021–2023
  1. ITI, Inc. $303 11 payments
  2. Teva Pharmaceuticals USA, Inc. $180 4 payments
  3. Alkermes, Inc. $160 5 payments
  4. AbbVie, Inc. $133 7 payments
  5. Lundbeck LLC $73 4 payments
  6. Otsuka America Pharmaceutical, Inc. $61 3 payments
  7. Neurocrine Biosciences, Inc. $43 2 payments
  8. Bausch Health US, LLC $40 3 payments
  9. BioCryst US Sales Co., LLC $27 1 payment
  10. Sunovion Pharmaceuticals Inc. $16 1 payment

Every payment, record by record

What the payments were for General payments · program years 2021–2023
  1. Food and Beverage $872 38 payments
  2. Education $164 3 payments
Products named General payments · program years 2021–2023
  1. CAPLYTA $303 11 payments
  2. LYBALVI Cns $160 5 payments
  3. VRAYLAR $133 7 payments
  4. LYBALVI Cns $107 3 payments
  5. ARISTADA Cns $82 4 payments
  6. ARISTADA Cns $82 4 payments
  7. LYBALVI Cns $79 1 payment
  8. LYBALVI Cns $79 1 payment
  9. AUSTEDO $69 3 payments
  10. REXULTI $61 3 payments
  11. Other $412 22 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

295

Median for Psychiatry: 574

Drug cost

$4,611

Median for Psychiatry: $27,624

Branded share of claims

10.5%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Lamotrigine Generic 59 $809
Divalproex Sodium Generic 27 $702
Quetiapine Fumarate Generic 47 $640
Lithium Carbonate Generic 15 $462
Lurasidone Hcl Generic 17 $350
Dextroamphetamine-Amphetamine Dextroamphetamine/Amphetamine Brand 12 $275
Duloxetine Hcl Generic 19 $268
Venlafaxine Hcl Er Venlafaxine Hcl Brand 19 $267
Risperidone Generic 18 $228
Trazodone Hcl Generic 20 $203

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Records

41 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record